In our trial, patients were treated with state-of-the-art pharmacological HF therapy: All patients received ARB/ACE-inhibitor therapy and beta-blocker therapy, and 97% of the study population received mineralocorticoid antagonist therapy. Here, ACE is linked to hydrops fetalis.